Intelligent Bio Solutions Inc. stock surges on technical breakout
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 03 2025
0mins
Should l Buy INBS?
Source: 8-K
Intelligent Bio Solutions Inc. shares rose significantly, crossing above the 5-day SMA, reflecting strong investor interest.
The stock's movement is attributed to a notable increase in trading volume, suggesting heightened market activity and interest in the company's potential growth. Investors are optimistic about the company's future prospects, which may have contributed to the surge in price.
This upward trend indicates a positive sentiment among investors, potentially leading to further gains if the momentum continues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INBS
About INBS
Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intelligent Bio Solutions Reports Strong Q3 Revenue Growth and Margin Expansion
- Significant Revenue Growth: Q3 cartridge revenue surged 59% year-over-year to $703,538, representing 66% of total quarterly sales, indicating strong performance under the recurring revenue model and expected to drive future market expansion.
- Robust Nine-Month Performance: Total revenue for the nine months ended March 31, 2026, reached $3.07 million, up 39% year-over-year, building on a $2.01 million first-half milestone, demonstrating sustained commercial momentum.
- Margin Expansion: The gross margin for Q3 hit 50.5%, up approximately 800 basis points from 46.8% in the prior year, reflecting successful operational efficiencies and increased sales volumes, enhancing unit economics.
- Market Investment Returns: The company's $1.77 million marketing investment over the past nine months directly contributed to 39% revenue growth, while Q3 marketing spend decreased by 42% year-over-year, indicating improved brand awareness and market presence.
See More
Intelligent Bio Solutions Reports Q3 Financial Results
- Financial Highlights: Intelligent Bio Solutions reported a Q3 GAAP EPS of -$1.80, indicating a loss; however, the company showed resilience with improvements in revenue and gross margin.
- Revenue Growth: The Q3 revenue reached $1.06 million with a gross profit margin of 50.5%, up from 46.8% in the same period last year, reflecting positive progress in cost management and sales strategies.
- Sales Performance: For the nine months ended March 31, 2026, cartridge sales totaled $1.86 million, a 46% year-over-year increase, representing 61% of total revenue, indicating strong product demand.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $6.86 million, significantly up from $740,371 at December 31, 2025, enhancing financial stability and future investment capacity.
See More
Intelligent Bio Solutions Launches Rapid Drug Testing Validation Study
- Significant Market Potential: The U.S. roadside drug testing market is projected to reach $1.62 billion by 2030, growing at a CAGR of 4.71%, providing INBS with substantial market opportunities amid rising drug-related accidents and fatalities.
- Analysis Time Reduction: The validation study aims to cut the analysis time of INBS's drug screening system from ten minutes to under three minutes, significantly enhancing law enforcement efficiency and improving road safety.
- Clear Technological Advantage: By providing rapid results, INBS's system not only meets the urgent needs of law enforcement for quick testing but also strengthens its market position as states expand drug testing programs following marijuana legalization.
- Diversified Market Expansion: Accelerated testing times will enable INBS to penetrate additional high-value sectors, such as drug treatment and consumer health markets, further enhancing its competitiveness in the global drug screening products market.
See More
Intelligent Bio Solutions Completes Penetration Testing for FDA Submission
- Successful Penetration Testing: Intelligent Bio Solutions Inc. has successfully completed penetration testing, identifying no major security vulnerabilities, which validates the robustness of its existing security infrastructure and strengthens its upcoming FDA 510(k) submission compliance.
- Security Upgrades Implemented: The company has implemented additional security upgrades in its drug testing technology, including enhanced encrypted identification tags and improved firmware safeguards, ensuring test integrity and protecting against cyber threats, thereby enhancing its commitment to data protection.
- Market Opportunity Expansion: By addressing security requirements early in the FDA 510(k) submission process, INBS positions its technology to meet evolving FDA guidance on medical device cybersecurity, and obtaining FDA clearance could open new revenue and expansion opportunities in the multi-billion-dollar U.S. drug screening market.
- Innovation Potential: INBS's Intelligent Fingerprinting Drug Screening System aims to revolutionize portable testing through fingerprint sweat analysis, providing results in under ten minutes, which is expected to become a valuable tool for employers in safety-critical industries, further driving the company's growth in global markets.
See More
Intelligent Bio Solutions Completes Initial Clinical Study for FDA Approval
- Clinical Study Completion: Intelligent Bio Solutions (INBS) announced the successful completion of its initial clinical study, which is essential for seeking FDA approval for its fingerprint-based drug testing system, yet this positive update did not prevent shares from plummeting nearly 20% in pre-market trading.
- Detection Capability Validation: The study evaluated the device's ability to detect codeine in 40 adults and confirmed its accuracy using standard laboratory testing methods, providing a scientific basis for future market applications despite the stock's poor performance.
- Project Advancement: INBS has commenced the second phase of its program, expected to be completed by June 2026, indicating the company's ongoing commitment to product development, even as market reactions remain unfavorable.
- Stock Price Volatility: Following a 7% decline in the previous trading session, INBS's stock fell sharply again after this announcement, reflecting investor concerns about the company's future prospects, which could impact its financing and market confidence.
See More
Intelligent Bio Solutions Advances FDA Submission for Drug Screening System
- Clinical Study Success: Intelligent Bio Solutions has completed a clinical Cut-off study involving 40 adults, validating the effectiveness of its Intelligent Fingerprinting Drug Screening System for codeine detection, providing robust data support for its FDA 510(k) submission and potentially accelerating its U.S. market entry.
- Multi-Site Study Initiation: The company has initiated the second phase of its clinical study program, which includes a multi-site Method Comparison and Usability Study aimed at validating the system's accuracy and user-friendliness, expected to be completed by the end of June 2026, thereby enhancing market confidence.
- Interference Study in Parallel: Alongside the Method Comparison study, the company will conduct an Interference Study to test the device against potentially interfering substances in real-world settings, anticipated to be completed by the end of July 2026, providing comprehensive assurance for market application.
- Significant Market Potential: The U.S. drug screening market represents a multi-billion-dollar annual opportunity, encompassing workplace testing, criminal justice, and substance abuse treatment, with the company's non-invasive fingerprint technology offering rapid and convenient advantages over traditional methods, likely leading to substantial commercial opportunities.
See More
Intelligent Bio Solutions Reports Strong Q3 Revenue Growth and Margin Expansion
- Significant Revenue Growth: Q3 cartridge revenue surged 59% year-over-year to $703,538, representing 66% of total quarterly sales, indicating strong performance under the recurring revenue model and expected to drive future market expansion.
- Robust Nine-Month Performance: Total revenue for the nine months ended March 31, 2026, reached $3.07 million, up 39% year-over-year, building on a $2.01 million first-half milestone, demonstrating sustained commercial momentum.
- Margin Expansion: The gross margin for Q3 hit 50.5%, up approximately 800 basis points from 46.8% in the prior year, reflecting successful operational efficiencies and increased sales volumes, enhancing unit economics.
- Market Investment Returns: The company's $1.77 million marketing investment over the past nine months directly contributed to 39% revenue growth, while Q3 marketing spend decreased by 42% year-over-year, indicating improved brand awareness and market presence.
See More
Intelligent Bio Solutions Reports Q3 Financial Results
- Financial Highlights: Intelligent Bio Solutions reported a Q3 GAAP EPS of -$1.80, indicating a loss; however, the company showed resilience with improvements in revenue and gross margin.
- Revenue Growth: The Q3 revenue reached $1.06 million with a gross profit margin of 50.5%, up from 46.8% in the same period last year, reflecting positive progress in cost management and sales strategies.
- Sales Performance: For the nine months ended March 31, 2026, cartridge sales totaled $1.86 million, a 46% year-over-year increase, representing 61% of total revenue, indicating strong product demand.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $6.86 million, significantly up from $740,371 at December 31, 2025, enhancing financial stability and future investment capacity.
See More
Intelligent Bio Solutions Launches Rapid Drug Testing Validation Study
- Significant Market Potential: The U.S. roadside drug testing market is projected to reach $1.62 billion by 2030, growing at a CAGR of 4.71%, providing INBS with substantial market opportunities amid rising drug-related accidents and fatalities.
- Analysis Time Reduction: The validation study aims to cut the analysis time of INBS's drug screening system from ten minutes to under three minutes, significantly enhancing law enforcement efficiency and improving road safety.
- Clear Technological Advantage: By providing rapid results, INBS's system not only meets the urgent needs of law enforcement for quick testing but also strengthens its market position as states expand drug testing programs following marijuana legalization.
- Diversified Market Expansion: Accelerated testing times will enable INBS to penetrate additional high-value sectors, such as drug treatment and consumer health markets, further enhancing its competitiveness in the global drug screening products market.
See More
Intelligent Bio Solutions Completes Penetration Testing for FDA Submission
- Successful Penetration Testing: Intelligent Bio Solutions Inc. has successfully completed penetration testing, identifying no major security vulnerabilities, which validates the robustness of its existing security infrastructure and strengthens its upcoming FDA 510(k) submission compliance.
- Security Upgrades Implemented: The company has implemented additional security upgrades in its drug testing technology, including enhanced encrypted identification tags and improved firmware safeguards, ensuring test integrity and protecting against cyber threats, thereby enhancing its commitment to data protection.
- Market Opportunity Expansion: By addressing security requirements early in the FDA 510(k) submission process, INBS positions its technology to meet evolving FDA guidance on medical device cybersecurity, and obtaining FDA clearance could open new revenue and expansion opportunities in the multi-billion-dollar U.S. drug screening market.
- Innovation Potential: INBS's Intelligent Fingerprinting Drug Screening System aims to revolutionize portable testing through fingerprint sweat analysis, providing results in under ten minutes, which is expected to become a valuable tool for employers in safety-critical industries, further driving the company's growth in global markets.
See More
Intelligent Bio Solutions Completes Initial Clinical Study for FDA Approval
- Clinical Study Completion: Intelligent Bio Solutions (INBS) announced the successful completion of its initial clinical study, which is essential for seeking FDA approval for its fingerprint-based drug testing system, yet this positive update did not prevent shares from plummeting nearly 20% in pre-market trading.
- Detection Capability Validation: The study evaluated the device's ability to detect codeine in 40 adults and confirmed its accuracy using standard laboratory testing methods, providing a scientific basis for future market applications despite the stock's poor performance.
- Project Advancement: INBS has commenced the second phase of its program, expected to be completed by June 2026, indicating the company's ongoing commitment to product development, even as market reactions remain unfavorable.
- Stock Price Volatility: Following a 7% decline in the previous trading session, INBS's stock fell sharply again after this announcement, reflecting investor concerns about the company's future prospects, which could impact its financing and market confidence.
See More
Intelligent Bio Solutions Advances FDA Submission for Drug Screening System
- Clinical Study Success: Intelligent Bio Solutions has completed a clinical Cut-off study involving 40 adults, validating the effectiveness of its Intelligent Fingerprinting Drug Screening System for codeine detection, providing robust data support for its FDA 510(k) submission and potentially accelerating its U.S. market entry.
- Multi-Site Study Initiation: The company has initiated the second phase of its clinical study program, which includes a multi-site Method Comparison and Usability Study aimed at validating the system's accuracy and user-friendliness, expected to be completed by the end of June 2026, thereby enhancing market confidence.
- Interference Study in Parallel: Alongside the Method Comparison study, the company will conduct an Interference Study to test the device against potentially interfering substances in real-world settings, anticipated to be completed by the end of July 2026, providing comprehensive assurance for market application.
- Significant Market Potential: The U.S. drug screening market represents a multi-billion-dollar annual opportunity, encompassing workplace testing, criminal justice, and substance abuse treatment, with the company's non-invasive fingerprint technology offering rapid and convenient advantages over traditional methods, likely leading to substantial commercial opportunities.
See More
